Stephens Inc. AR Has $171,000 Stake in Cerus Co. (NASDAQ:CERS)

Stephens Inc. AR lessened its stake in shares of Cerus Co. (NASDAQ:CERS) by 13.1% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 98,169 shares of the biotechnology company’s stock after selling 14,785 shares during the period. Stephens Inc. AR’s holdings in Cerus were worth $171,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Hood River Capital Management LLC acquired a new position in shares of Cerus during the 1st quarter valued at $566,000. The Manufacturers Life Insurance Company lifted its position in shares of Cerus by 10.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 73,372 shares of the biotechnology company’s stock valued at $129,000 after acquiring an additional 7,209 shares during the period. Price T Rowe Associates Inc. MD lifted its position in shares of Cerus by 4.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 192,873 shares of the biotechnology company’s stock valued at $365,000 after acquiring an additional 8,982 shares during the period. Russell Investments Group Ltd. lifted its position in shares of Cerus by 451.1% during the 1st quarter. Russell Investments Group Ltd. now owns 14,879 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 12,179 shares during the period. Finally, Assenagon Asset Management S.A. lifted its position in shares of Cerus by 7.1% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,186,564 shares of the biotechnology company’s stock valued at $2,088,000 after acquiring an additional 78,824 shares during the period. Institutional investors and hedge funds own 78.37% of the company’s stock.

Cerus Stock Performance

NASDAQ CERS opened at $1.78 on Friday. Cerus Co. has a 1 year low of $1.38 and a 1 year high of $2.59. The company has a debt-to-equity ratio of 1.19, a current ratio of 2.59 and a quick ratio of 1.92. The firm has a market cap of $330.57 million, a price-to-earnings ratio of -16.18 and a beta of 1.20. The company has a fifty day moving average price of $1.81 and a 200-day moving average price of $1.92.

Wall Street Analysts Forecast Growth

Separately, Stifel Nicolaus lowered their price objective on shares of Cerus from $6.00 to $3.00 and set a “buy” rating on the stock in a report on Thursday, October 17th.

Insider Transactions at Cerus

In related news, CFO Kevin Dennis Green sold 28,385 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $2.18, for a total transaction of $61,879.30. Following the completion of the transaction, the chief financial officer now owns 590,365 shares in the company, valued at approximately $1,286,995.70. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 3.40% of the company’s stock.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.